Avastin approved for recurrent ovarian and related cancers

Avastin (bevacizumab) has been approved for the treatment of recurrent ovarian and related cancers.

The initial infusion of bevacizumab must be given over 90 minutes to minimise the risk of a hypersensitivity reaction.
The initial infusion of bevacizumab must be given over 90 minutes to minimise the risk of a hypersensitivity reaction.

A phase III double-blind placebo-controlled trial (AVF4095g) in 484 patients showed that the monoclonal antibody improved outcomes in this setting when added to standard platinum-based chemotherapy (carboplatin plus gemcitabine).


Patients who had histologically documented disease recurrence within 6 months of previous platinum-based chemotherapy and had not received carboplatin or gemcitabine in the recurrent setting were included in the study. Those who had received prior therapy with bevacizumab or other VEGF-targeting agents were excluded.

Patients received a standard backbone of carboplatin and gemcitabine plus either placebo or bevacizumab 15mg/kg by intravenous infusion every 3 weeks at the same time as the chemotherapy for 6-10 cycles, then continued as monotherapy until disease progression.

Survival benefit

Median progression-free survival based on investigator assessment using modified RECIST criteria (the primary endpoint) was significantly higher in the bevacizumab group than in the placebo group: 12.4 vs 8.4 months (p<0.0001). Similar results were observed when the primary endpoint was independently reviewed.

View Avastin drug record
Further information: Roche

Follow MIMS on Twitter

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases